PROACTIVE: Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet
Brief description of study
Approximately 50% of patients with celiac disease have continued symptoms despite at least 12 months of treatment with a gluten free diet.
PRV-015, a mAb that blocks IL-15, has been shown to reduce intestinal inflammation and improve clinical symptoms induced by gluten consumption in a previous Phase 2a gluten-challenge study in patients with celiac disease. PRV-015 may be effective as an adjunctive treatment to a gluten free diet.
Patients will be recruited first from the PI's own practice and then within the Division of Gastroenterology at Penn. For eligibility consideration, please contact the research team by filling the form below.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
celiac disease,gluten-free,diet
-
Age: Between 18 Years - 70 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 843779
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
